Search research articles
Contact Us
Filters
Showing results (151-160 of 217) with videos related to
Page
of 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 12, 2026
The Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations
Merve Kaya, Lawrence H Lin, Jan Oosting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
Gynecologic Oncology
|
February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study
Florence Joly, Michel Fabbro, Philippe Follana, et al.
Gynecologic Oncology
|
August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M O'Malley, Ana Oaknin, Bradley J Monk, et al.
The Journal of Pathology
|
May 17, 2021
SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type
Mamy Andrianteranagna, Joanna Cyrta, Julien Masliah-Planchon, et al.
JCO Oncology Practice
|
November 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer
Claudia Marchetti, Gwenael Ferron, Olivier Colomban, et al.
Gynecologic Oncology
|
December 13, 2024
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
Henri Azaïs, Camille Brochard, Valérie Taly, et al.
Genome Medicine
|
December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2018
Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Marthe M de Jonge, Aurélie Auguste, Lise M van Wijk, et al.
Page
of 22
Search research articles
Search
Showing results (151-160 of 217) with videos related to
Sort By:
Page
of 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 12, 2026
The Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations
Merve Kaya, Lawrence H Lin, Jan Oosting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
Gynecologic Oncology
|
February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study
Florence Joly, Michel Fabbro, Philippe Follana, et al.
Gynecologic Oncology
|
August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M O'Malley, Ana Oaknin, Bradley J Monk, et al.
The Journal of Pathology
|
May 17, 2021
SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type
Mamy Andrianteranagna, Joanna Cyrta, Julien Masliah-Planchon, et al.
JCO Oncology Practice
|
November 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer
Claudia Marchetti, Gwenael Ferron, Olivier Colomban, et al.
Gynecologic Oncology
|
December 13, 2024
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
Henri Azaïs, Camille Brochard, Valérie Taly, et al.
Genome Medicine
|
December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2018
Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Marthe M de Jonge, Aurélie Auguste, Lise M van Wijk, et al.
Page
of 22